"After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactivity elimination, accounting for approximately 85% of the dose, while fecal excretion represented approximately 6% of the dose. Nepafenac (prodrug) and amfenac (active compound) were not quantifiable in the urine."@en . "Nepafenacum"@en . . "approved"@en . . "AL-6515"@en . . "# Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10850857 # Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10850858 # Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17189793 # Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17720067 # Bucci FA Jr, Waterbury LD: Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18655957 # Summary Basis of Decision (SBD): NEVANAC. \"Health Canada\":http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2008_nevanac_114004-eng.php"@en . . . . . . . . . . . . . . "For the treatment of pain and inflammation associated with cataract surgery."@en . . . "Amfenac amide"@en . "Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery."@en . . . "Ocularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery."@en . . " "@en . . . . . "78281-72-8"@en . . . . . . "Nevanac"@en . "Nepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro)."@en . . . . . "Nepafenac"@en . . . . . . . . . "Nepafenac is a prodrug. After penetrating the cornea, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity."@en . "2-amino-3-Benzoylbenzeneacetamide"@en . . . "Amfenac has high affinity toward serum albumin proteins. In vitro, the percent bound to human albumin and human serum was 95.4% and 99.1% respectively."@en . "AHR 9434"@en . . "AL 6515"@en . "Nepafenaco"@en . "AHR-9434"@en .